Copyrights on musical compositions or novels typically last 50 to 70 years after the creator's death. It's a shame that this doesn't apply to drug firms, because Forest Labs (NYSE:FRX) is facing the unpleasant prospect of patent expiration for its two biggest-selling drugs - after which generic drugs can begin stealing market share and revenue.

Top Two Drugs Drew 90% Of Third-Quarter Sales
Forest has little hope of staving off either of these coming expirations to generic competition from the likes of Teva Pharmaceutical Industries (Nasdaq:TEVA) and Mylan (Nasdaq:MYL), which is scheduled for the depression treatment drug Lexapro in early 2012 and roughly a year later for Namenda, which is primarily used to treat Alzheimer's disease. This is unfortunate, as Lexapro accounted for 64%, or $585.5 million of total third-quarter net sales of $920 million, results of which were reported January 20. Namenda accounted for another 26% of sales, demonstrating the extent of the top-line hole Forest will have to dig itself out of in just a few short years. (For more on evaluating drug companies, check out Measuring The Medicine Makers.)

Can Pipeline Offset Upcoming Expiries?
Analyst opinions are mixed about whether Forest has a strong enough pipeline to offset the upcoming expiries. Bystolic, which is used to treat hypertension, was released on the market but posted Q3 sales of only $21 million, although Forest is readying new drug applications for additional usage such as treating congestive heart failure. Other products on the market, such as AeroBid, AeroChamber and Campral reported very small quarterly sales compared to Forest's two blockbuster drugs.

Management believes that its late-stage pipeline "could collectively represent several billion dollars of potential product sales in the long-term sufficient to replace the revenues lost to the patent expiries for Lexapro and Namenda combined". Of course, it also conceded that this scenario might not turn out to be quite so rosy. The company must keep the pedal to the metal in terms of its earlier-stage pipeline, continuing to work with partners in licensing drugs and potentially acquiring competitors, such as the January 2007 purchase of privately held biotech firm Cerexa. (Learn how to evaluate an acquisition in The Merger - What To Do When Companies Converge.)

Profit Potential Is Significant In Immediate Future
Forest could also turn into prey if a giant pharmaceutical firm such as Merck (NYSE:MRK) or Eli Lilly (NYSE:LLY) finds its pipeline prospects promising. Also appealing to potential suitors, Forest is sitting on approximately $2 billion in cash, no long-term debt and is churning out in excess of $1 billion in operating cash flow while Lexapro and Namenda remain patent-protected. In other words, profit potential is significant for the next couple of years as illustrated by the $188 million in Q3 net income, or 62 cents per share, or 19% of net sales.

Final Thoughts
Finally, Forest's valuation is low with a fiscal 2009 forward P/E multiple of just over 7 based on the $3.35-$3.45 earnings guidance that management provided when it released Q3 results. Uncertainty lurks when looking out past 2011, but a fair amount of downside is already priced into the shares. Plus, Forest can pull a number of levers to enhance shareholder value going forward, and unlike a large pharmaceutical company, a couple of successful drugs could have a significantly beneficial impact on sales and profits.

Related Articles
  1. Options & Futures

    What Does Quadruple Witching Mean?

    In a financial context, quadruple witching refers to the day on which contracts for stock index futures, index options, and single stock futures expire.
  2. Options & Futures

    4 Equity Derivatives And How They Work

    Equity derivatives offer retail investors opportunities to benefit from an underlying security without owning the security itself.
  3. Stock Analysis

    Analyzing Altria's Return on Equity (ROE) (MO)

    Learn about Altria Group's return on equity (ROE) and analyze net profit margin, asset turnover and financial leverage to determine what is causing its high ROE.
  4. Investing News

    Icahn's Bet on Cheniere Energy: Should You Follow?

    Investing legend Carl Icahn continues to lose money on Cheniere Energy, but he's increasing his stake. Should you follow his lead?
  5. Stock Analysis

    Analyzing Google's Return on Equity (ROE) (GOOGL)

    Learn about Alphabet's return on equity. How has its ROE changed over time, how does it compare to its peers and what factors are driving ROE for the company?
  6. Investing News

    Is Buffett's Bet on Oil Right for You? (XOM, PSX)

    Oil stocks are getting trounced, but Warren Buffett still likes one of them. Should you follow the leader?
  7. Options & Futures

    Five Advantages of Futures Over Options

    Futures have a number of advantages over options such as fixed upfront trading costs, lack of time decay and liquidity.
  8. Investing News

    Chipotle Served with Criminal Probe

    Chipotle's beat muted expectations and got a clear bill from the CDC, but it now appears that an investigation into its E.coli breakout has expanded.
  9. Stock Analysis

    Analyzing Sprint Corp's Return on Equity (ROE) (S)

    Learn about Sprint's return on equity. Find out why its ROE is negative and how asset turnover and financial leverage impact ROE relative to Sprint's peers.
  10. Stock Analysis

    Why Alphabet is the Best of the 'FANGs' for 2016

    Alphabet just impressed the street, but is it the best FANG stock?
  1. What is a derivative?

    A derivative is a contract between two or more parties whose value is based on an agreed-upon underlying financial asset, ... Read Full Answer >>
  2. What is after-hours trading? Am I able to trade at this time?

    After-hours trading (AHT) refers to the buying and selling of securities on major exchanges outside of specified regular ... Read Full Answer >>
  3. How do hedge funds use equity options?

    With the growth in the size and number of hedge funds over the past decade, the interest in how these funds go about generating ... Read Full Answer >>
  4. Can mutual funds invest in options and futures? (RYMBX, GATEX)

    Mutual funds invest in not only stocks and fixed-income securities but also options and futures. There exists a separate ... Read Full Answer >>
  5. How do dividends affect retained earnings?

    When a company issues a cash dividend to its shareholders, the retained earnings listed on the balance sheet are reduced ... Read Full Answer >>
  6. What is the difference between called-up share capital and paid-up share capital?

    The difference between called-up share capital and paid-up share capital is investors have already paid in full for paid-up ... Read Full Answer >>
Trading Center